PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,735,384 | -46.0% | 56,564 | -29.5% | 0.00% | 0.0% |
| Q2 2023 | $3,215,658 | +41.5% | 80,251 | +44.2% | 0.00% | 0.0% |
| Q1 2023 | $2,271,770 | -63.8% | 55,667 | -65.7% | 0.00% | -66.7% |
| Q4 2022 | $6,271,654 | +89.0% | 162,436 | +160.4% | 0.00% | +50.0% |
| Q3 2022 | $3,318,000 | -9.5% | 62,387 | -0.8% | 0.00% | 0.0% |
| Q2 2022 | $3,666,000 | -16.6% | 62,875 | +9.2% | 0.00% | 0.0% |
| Q1 2022 | $4,395,000 | -1.9% | 57,583 | -22.6% | 0.00% | 0.0% |
| Q4 2021 | $4,479,000 | +7.6% | 74,442 | +0.1% | 0.00% | 0.0% |
| Q3 2021 | $4,164,000 | -10.6% | 74,354 | -3.1% | 0.00% | 0.0% |
| Q2 2021 | $4,657,000 | -9.1% | 76,754 | +5.0% | 0.00% | 0.0% |
| Q1 2021 | $5,123,000 | +18.2% | 73,094 | +0.9% | 0.00% | 0.0% |
| Q4 2020 | $4,333,000 | -0.9% | 72,414 | -0.4% | 0.00% | 0.0% |
| Q3 2020 | $4,372,000 | +13.1% | 72,714 | -1.3% | 0.00% | 0.0% |
| Q2 2020 | $3,867,000 | +77.8% | 73,704 | +13.6% | 0.00% | 0.0% |
| Q1 2020 | $2,175,000 | -25.9% | 64,864 | +0.1% | 0.00% | 0.0% |
| Q4 2019 | $2,936,000 | +19.4% | 64,814 | +0.4% | 0.00% | 0.0% |
| Q3 2019 | $2,458,000 | -0.9% | 64,564 | +13.2% | 0.00% | 0.0% |
| Q2 2019 | $2,480,000 | +14.2% | 57,030 | 0.0% | 0.00% | +100.0% |
| Q1 2019 | $2,171,000 | -11.5% | 57,030 | 0.0% | 0.00% | -50.0% |
| Q4 2018 | $2,453,000 | -12.5% | 57,030 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $2,803,000 | +53.3% | 57,030 | 0.0% | 0.00% | +100.0% |
| Q2 2018 | $1,828,000 | +0.1% | 57,030 | -2.8% | 0.00% | 0.0% |
| Q1 2018 | $1,827,000 | -31.3% | 58,648 | +0.7% | 0.00% | -50.0% |
| Q4 2017 | $2,658,000 | +21.5% | 58,230 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,187,000 | -43.1% | 58,230 | -27.8% | 0.00% | -33.3% |
| Q2 2017 | $3,845,000 | +1.8% | 80,610 | -2.7% | 0.00% | 0.0% |
| Q1 2017 | $3,776,000 | +88.8% | 82,810 | +33.7% | 0.00% | +50.0% |
| Q4 2016 | $2,000,000 | -5.6% | 61,930 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $2,119,000 | +1.4% | 61,930 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $2,089,000 | -36.3% | 61,930 | -0.0% | 0.00% | -33.3% |
| Q1 2016 | $3,282,000 | -31.0% | 61,947 | +0.0% | 0.00% | -25.0% |
| Q4 2015 | $4,756,000 | +81.0% | 61,930 | -3.1% | 0.00% | +100.0% |
| Q3 2015 | $2,628,000 | -43.7% | 63,930 | -3.1% | 0.00% | -50.0% |
| Q2 2015 | $4,668,000 | -79.8% | 66,000 | -74.6% | 0.00% | -78.9% |
| Q1 2015 | $23,119,000 | -36.0% | 260,200 | -36.1% | 0.02% | -36.7% |
| Q4 2014 | $36,098,000 | -27.2% | 407,149 | -20.4% | 0.03% | -28.6% |
| Q3 2014 | $49,578,000 | -16.3% | 511,533 | -20.6% | 0.04% | -16.0% |
| Q2 2014 | $59,218,000 | +15.8% | 644,654 | -11.8% | 0.05% | +13.6% |
| Q1 2014 | $51,127,000 | -31.8% | 730,488 | -44.0% | 0.04% | -34.3% |
| Q4 2013 | $74,948,000 | +6.7% | 1,303,672 | -10.7% | 0.07% | -2.9% |
| Q3 2013 | $70,210,000 | +66.5% | 1,459,979 | +0.4% | 0.07% | +53.3% |
| Q2 2013 | $42,158,000 | – | 1,453,731 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |